1424 PARTIAL NEPHRECTOMY FOR RENAL MASSES > 7CM IS TECHNICALLY FEASIBLE, ONCOLOGICALLY SOUND, AND PRESERVES RENAL FUNCTION (2012)

You have accessJournal of UrologyKidney Cancer: Localized III1 Apr 20121424 PARTIAL NEPHRECTOMY FOR RENAL MASSES > 7CM IS TECHNICALLY FEASIBLE, ONCOLOGICALLY SOUND, AND PRESERVES RENAL FUNCTION Christopher Long, Daniel J. Canter, Brian Cronson, Alexander Kutikov, Tianyu Li, Rosalia Viterbo, David Y.T. Chen, Richard Greenberg, and Robert Uzzo Christopher LongChristopher Long Philadelphia, PA More articles by this author , Daniel J. CanterDaniel J. Canter Atlanta, GA More articles by this author , Brian CronsonBrian Cronson Philadelphia, PA More articles by this author , Alexander KutikovAlexander Kutikov Philadelphia, PA More articles by this author , Tianyu LiTianyu Li Philadelphia, PA More articles by this author , Rosalia ViterboRosalia Viterbo Philadelphia, PA More articles by this author , David Y.T. ChenDavid Y.T. Chen Philadelphia, PA More articles by this author , Richard GreenbergRichard Greenberg Philadelphia, PA More articles by this author , and Robert UzzoRobert Uzzo Philadelphia, PA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1897AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Partial nephrectomy (PN) preserves renal function and has demonstrated oncologic equivalence to radical nephrectomy (RN) in T1a/b renal tumors. To date, reports of PN for tumors >7cm (pT2) are sparse and reveal contradictory oncologic outcomes. We assessed our institutional series of patients undergoing PN for renal masses >pT2 and compared outcomes to reported literature. METHODS We reviewed our prospectively maintained institutional kidney cancer database of over 2000 patients and identified 52 patients who underwent PN for tumors > 7 cm. Demographic, clinical, and survival data were analyzed. RESULTS Median patient age and tumor size were 59 years (range=21-83) and 8.5 cm (range=7-30), respectively. Pre-operatively, 21 (40.3%) patients had CKD Stage III or higher. 23 (46.9%) patients had an absolute indication for NSS, 7 (14.3%) patients had a solitary kidney and 16 (32.7%) patients had bilateral tumors. Malignancy rate was 80 percent with clear cell (36.5%) and papillary (34.6%) histologies identified most commonly upon resection. Five and 10-year overall and RCC-specific survival rates were 94.8% and 75.9%, respectively. A total of five (10.2%) patients developed recurrent disease, and three (6.1%) patients died of metastatic RCC. These findings are compared to prior reports (Table I). CONCLUSIONS Previous reports suggest that PN for tumors > 7cm may be associated with decreased oncologic efficacy compared to RN. Here we present the largest single institutional series and a pooled analysis noting that PN can safely be performed in tumors >7 cm, and long-term cancer free survival can be achieved with minimal compromise of renal function. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e578 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christopher Long Philadelphia, PA More articles by this author Daniel J. Canter Atlanta, GA More articles by this author Brian Cronson Philadelphia, PA More articles by this author Alexander Kutikov Philadelphia, PA More articles by this author Tianyu Li Philadelphia, PA More articles by this author Rosalia Viterbo Philadelphia, PA More articles by this author David Y.T. Chen Philadelphia, PA More articles by this author Richard Greenberg Philadelphia, PA More articles by this author Robert Uzzo Philadelphia, PA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...